{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-277515","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.121820+00:00","generated_at":"2026-05-16T20:57:44.049489+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"confidence":"high","headline":"Lyra Therapeutics reports Q3 net loss $6.0M, plans new Phase 3 trial for LYR-210","bullets":["Cash and cash equivalents $22.1M at Sep 30, 2025; cash runway into Q3 2026.","Net loss for Q3 2025 was $6.0M, down from $11.9M in Q3 2024.","R&D expenses decreased 32% to $4.0M; G&A decreased 43% to $2.2M due to cost reductions.","Planning confirmatory Phase 3 trial of LYR-210 for CRS without nasal polyps following FDA meeting.","Presented positive ENLIGHTEN 2 Phase 3 results at AAO-HNS meeting in October 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-277515","json":"https://secwatch.observer/filing/0001193125-25-277515.json","markdown":"https://secwatch.observer/filing/0001193125-25-277515.md","text":"https://secwatch.observer/filing/0001193125-25-277515.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000119312525277515/0001193125-25-277515-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000119312525277515/lyra-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:57:44.049489+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}